摘要
Chronic obstructive pulmonary disease （COPD） is the most common chronic airway disease affecting Chinese population and it ranks number tour leading cause of death. The high mortality and morbidity, increased prevalence, significant loss of labor, and high medical expenditure warrants attention from the health organization and society to standardize the diagnosis and treatment of COPD. Overall COPD treatment efficacy has been significantly improved with application of long activating bronchial dilator （LABD）, due to the imbalance and geographically different distribution of medical resource and education, standardized treatment under COPD guideline remain the major protocol in a long time period in the future.
Chronic obstructive pulmonary disease （COPD） is the most common chronic airway disease affecting Chinese population and it ranks number tour leading cause of death. The high mortality and morbidity, increased prevalence, significant loss of labor, and high medical expenditure warrants attention from the health organization and society to standardize the diagnosis and treatment of COPD. Overall COPD treatment efficacy has been significantly improved with application of long activating bronchial dilator （LABD）, due to the imbalance and geographically different distribution of medical resource and education, standardized treatment under COPD guideline remain the major protocol in a long time period in the future.
